MRK - Public offerings

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206Strong early partnering interest underscores industry confidence in Formycon's biosimilar expertise and development excellenceAgreement structure includes in total mid-teens-million-euro upfront and 2025 milestone payments, alongside additional development and regulatory milestones and a mid-double-digit-gross-profit-share upon launchClinical development phase of FYB206 nearly completed; primary endpoint data expected in the first quarter of 2026 PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced its inaugural issuance of a $1 billion sustainability bond, which was part of an $8 billion underwritten public offering of notes that closed on Dec. 10, 2021. Merck's environmental, social and governance (ESG) efforts are grounded in the core values that have always guided the company's mission to invent for life, with a responsibility to patients and animals in need of medicines and vaccines, and with respect, inclusion and accountability to its employees. The company's 130-year legacy has been built on the understanding that operating responsibly, enabling access to health for the patients and communiti

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today priced an $8.0 billion public offering of five series of senior unsecured notes (collectively, the "notes"). The notes include: $1.5 billion of 1.700% notes due 2027 (the "2027 notes") $1.0 billion of 1.900% notes due 2028 (the "sustainability notes") $2.0 billion of 2.150% notes due 2031 (the "2031 notes") $2.0 billion of 2.750% notes due 2051 (the "2051 notes") $1.5 billion of 2.900% notes due 2061 (the "2061 notes") Merck intends to use the net proceeds from the offering of the 2027 notes, the 2031 notes, the 2051 notes and the 2061 notes for general corporate purposes, including without limitation the repay

Appointed Andrew Hall, Chief Business Officer, as interim CEO, Jeremy Graff, PhD as Chief Scientific Officer, Stanley Frankel, MD and Jose Iglesias, MD as Clinical Advisors Strengthened financial position and extended cash runway with the completion of a $25M financing resulting in pro-forma cash and cash equivalents of $45.8 million on June 30th, 2021 Completed the DeCidE1 Phase 2 clinical study in advanced, recurrent ovarian cancer. Translational analyses confirm generation of tumor-antigen directed T cells by maveropepimut-S Initiated Phase 2B trial in relapsed/refractory DLBCL Expanded presence in the US with a corporate office in Cambridge, Massachusetts biotech hub IMV

2020 marked year of notable progress for Oncorus. Key highlights included: Transitioned to clinical-stage company with initiation of Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of solid tumorsAnnounced clinical trial collaboration and supply agreement with Merck to evaluate combination of ONCR-177 with KEYTRUDA® (pembrolizumab) as part of ongoing ONCR-177 Phase 1 clinical trialCompleted IPO, receiving $98.4 million in aggregate gross proceedsCommenced strategic planning for operational and manufacturing scale-up, including signing of a 15-year lease to build a state-of-the-art, 88,000 square foot GMP viral immunotherapy clinical manufacturing fac